Status:
UNKNOWN
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
Lead Sponsor:
HealthTree Foundation
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Multiple Myeloma
Smoldering Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a q...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma.
- Access to a computer or electronic device with internet access, or phone
- Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma
- Willing to give electronically-signed consent
- Ability to read questions in English
Exclusion
Key Trial Info
Start Date :
January 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04727294
Start Date
January 22 2021
End Date
December 1 2021
Last Update
August 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HealthTree.org (Online)
Lehi, Utah, United States, 84043